Evidence map›Paper›PMID 41168323›Full record

ArticleScientific reports2025

The effect of molecular weight of hyaluronic acid on corneal cell viability.

Joo-Hee Park, Choul Yong Park

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joo-Hee ParkDepartment of Ophthalmology, Dongguk University Ilsan Hospital, Goyang, South Korea.
Choul Yong ParkDepartment of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea. oph0112@gmail.com.

Funding

Korea Health Industry Development Institute RS-2023-KH135936
6 · The paper itself

Abstract

Hyaluronic acid (HA) is widely utilized in ophthalmology for its viscoelastic and wound-healing properties; however, its effects vary according to molecular weight (MW). This study evaluates the toxicity induced by HA across corneal epithelial cells, keratocytes, and endothelial cells to ensure its safe clinical application. Human corneal epithelial cells, keratocytes, and endothelial cells were cultured under standardized conditions. Viability was assessed using the Cell Counting Kit-8 (CCK-8) and the live/dead cell staining after exposure to HA of varying MW. The MW categories were very low (VLMW, MW range from 8000 to 15,000 Da), low (LMW, MW range from 130,000 to 150,000 Da), medium (MMW, MW range from 750,000 to 1,000,000 Da), and high (HMW, MW range over 1,000,000 Da)), at concentrations ranging from 0.025% to 0.5% for durations of 24, 48, and 72 h. LMW HA exhibited the highest toxicity across all layers of corneal cells, demonstrating a dose-dependent decrease in cell viability. In epithelial cells specifically, 0.5% LMW HA resulted in a reduction of viability by more than 50% within 24-72 h, with concentrations greater than or equal to 0.25% proving hazardous after 24 h. Keratocytes experienced toxicity across all HA MW, with LMW HA leading to the most significant reductions. In corneal endothelial cells, LMW HA decreased viability by more than 50% after 48 h. Conversely, VLMW HA and HMW HA showed minimal toxicity. These findings highlight the importance of selecting appropriate HA formulations based on MW to ensure both efficacy and safety in ophthalmic treatments.

Indexed as

CorneaCorneal KeratocytesHyaluronic AcidCells, CulturedCell SurvivalEndothelial CellsEpithelial CellsEpithelium, CornealHumansMolecular WeightHyaluronic AcidCellsCorneaHyaluronic acidMolecular weightToxicityViability

Identifiers

PMID41168323
PMCPMC12575829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.